Amgen Inc. Reports Positive Phase 3 Results for Dazodalibep in Sjögren’s Disease and Highlights Repatha’s Cost‑Effectiveness

Amgen Inc. (NASDAQ: AMGN) announced two sets of data that reinforce the company’s therapeutic portfolio in the first half of 2026.

1. Phase 3 OASIZ‑301 Results for Dazodalibep

On 11 November 2026, Amgen disclosed the topline results of the global Phase 3 OASIZ‑301 study evaluating dazodalibep in patients with Sjögren’s disease. The trial demonstrated clinically meaningful improvements in systemic disease activity and patient‑reported symptoms. These findings build on the positive topline data released in September 2026 and represent the only global Phase 3 trial to show such benefits in this patient population.

2. Repatha (Evolocumab) Cost‑Effectiveness and Cardiovascular Outcomes

Amgen presented new evidence at the American Heart Association (AHA) Scientific Sessions 2026 that further supports the value of Repatha. Independent analyses of individual participant data from the Phase 3 VESALIUS‑CV trial quantified the drug’s impact on low‑density lipoprotein cholesterol (LDL‑C) lowering, major cardiovascular events, and cost‑effectiveness.

  • Cost‑effectiveness – The first health‑economic analysis compared treatment costs with projected health benefits, showing Repatha to be highly cost‑effective in high‑risk patients who have not yet experienced a heart attack or stroke.
  • Cardiovascular benefit – A long‑term FOURIER external‑control analysis indicated a 29 % lower risk of major cardiovascular events in patients living with atherosclerotic cardiovascular disease (ASCVD) who received Repatha.

3. Market Context

  • Amgen’s share price closed at $468.11 on 10 November 2026, within the 52‑week range of $312.39 to $483.99.
  • The company’s market capitalization stands at approximately $251.7 billion.
  • The price‑earnings ratio is 26.89, reflecting investor expectations for continued growth in the biotechnology sector.

4. Strategic Implications

The positive Phase 3 outcomes for dazodalibep reinforce Amgen’s pipeline in autoimmune diseases, while the Repatha data strengthen the company’s position in the cardiovascular therapeutics market. Together, these results support Amgen’s strategy of advancing high‑impact biologics based on cellular and molecular biology.